Functional IL-33 (mouse) Antibody, mAb (recombinant) (blocking)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| E |
---|---|
Primary Accession | Q8BVZ5 |
Reactivity | Mouse |
Host | Purified From HEK 293 Cell culture Supernatant. |
Clonality | Monoclonal |
Isotype | Mouse IgG2b |
Gene Source | Mouse |
Endotoxin | <0.01EU/ µg purified protein (LAL test; Lonza). |
Application Note | E,Functional Applicational, Inhibits the binding of mouse IL-33 to ST2/IL-1RAcP. |
Clone Names | Bondy-1-1 |
Calculated MW | 29991 Da |
Description | anti-IL-33 (mouse), monoclonal antibody (recombinant) (Bondy-1-1) is composed of human variable regions (VH and VL) (λ-chain) of immunoglobulin fused to the mouse lgG2b Fc domain. |
Gene ID | 77125 |
---|---|
Other Names | Interleukin-33; IL-1F11; NF-HEV |
Target/Specificity | Recognizes mouse IL-33. |
Format | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
Reconstitution & Storage | Stable for at least 1 year after receipt when stored at -20°C. |
Precautions | Functional IL-33 (mouse) Antibody, mAb (recombinant) (blocking) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | Il33 {ECO:0000312|MGI:MGI:1924375} |
---|---|
Function | Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:29045903). Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines (By similarity). Also involved in activation of mast cells, basophils, eosinophils and natural killer cells (By similarity). Acts as an enhancer of polarization of alternatively activated macrophages (By similarity). Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury (By similarity). Induces rapid UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (PubMed:34644537). |
Cellular Location | Nucleus. Chromosome {ECO:0000250|UniProtKB:O95760}. Cytoplasm {ECO:0000250|UniProtKB:O95760}. Cytoplasmic vesicle, secretory vesicle {ECO:0000250|UniProtKB:O95760}. Secreted. Note=Secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore following cleavage by CELA1 (PubMed:35749514, PubMed:35794369) Associates with heterochromatin and mitotic chromosomes (By similarity). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10; it results in protein translocation from the cytoplasm into the ERGIC (endoplasmic reticulum- Golgi intermediate compartment) followed by vesicle entry and secretion (By similarity). {ECO:0000250|UniProtKB:O95760, ECO:0000269|PubMed:35749514, ECO:0000269|PubMed:35794369} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Interleukin-33 (IL-33; HF-NEV; IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis.
Anti-IL-33, mAb (recombinant) (blocking) (Bondy-1-1) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.